诺辉健康作为中国首家高发癌症居家早筛生物高科技企业，其研发的幽幽管®成为全球首个获IVDR Class C自测证书的幽门螺杆菌粪便抗原检测产品。2024年，诺辉健康将幽幽管IVDR认证全流程独家委托给先诺，目标是一次交卷、快速拿证。先诺通过双国临床（匈牙利和意大利）、高标准设计（以UBT呼气试验为对照，灵敏度、特异度终点分别锁定≥95%/≥99%）、可用性研究（100名普通用户错误率仅0.8%）及...
Source Link诺辉健康作为中国首家高发癌症居家早筛生物高科技企业，其研发的幽幽管®成为全球首个获IVDR Class C自测证书的幽门螺杆菌粪便抗原检测产品。2024年，诺辉健康将幽幽管IVDR认证全流程独家委托给先诺，目标是一次交卷、快速拿证。先诺通过双国临床（匈牙利和意大利）、高标准设计（以UBT呼气试验为对照，灵敏度、特异度终点分别锁定≥95%/≥99%）、可用性研究（100名普通用户错误率仅0.8%）及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.